Overview Latest Regional Industry Featured Multimedia Other Languages Public Company News
All APAC Global
All APAC Global
All APAC Global
All APAC Global
Daewoong Pharmaceutical Received GMP Certification from Brazilian ANVISA 2023-11-28 08:00
Maypharm Launches the world first Adipose Stem Cell Exosome hair filler, HAIRNA Exosome Hair Fill 2023-08-23 17:00
Daewoong Pharmaceutical Initiates Global Export of 'Novel Drug' Launching 'Fexuprazan' in the Philippines 2023-08-16 13:00
Maypharm Launches SEDY FILL, a hyaluronic acid body filler 2023-08-09 17:46
Daewoong Pharmaceutical submits a new drug application for Fexuprazan in China challenging the world's largest market for anti-ulcer drugs 2023-07-31 08:00
Daewoong Pharmaceutical has obtained approval for SGLT2i + metformin combination drug Envlomet 2023-07-19 08:52
Daewoong Pharmaceutical Publishes Molecular Mechanism of Bersiporocin as an Antifibrotic in EMBO Molecular Medicine 2023-05-26 06:00
Daewoong Pharmaceutical Presents New Clinical Data of Fexuprazan at Digestive Disease Week 2023 2023-05-19 20:00
Daewoong Pharmaceutical announces a Global License Agreement for DWP213388, a new drug candidate for autoimmune disease with Vitalli Bio 2023-04-28 08:58
Daewoong Pharmaceutical Announce Publication of Phase 3 Study of 'Envlo', a New Treatment for Diabetes, in the International SCIE Journal 2023-04-24 14:53
Daewoong Pharmaceutical and Sygnature Discovery announce drug discovery research collaboration 2023-04-18 17:16
Maypharm's Hyalmass filler with Hybrid Technology obtained CE to hit Europe and America's market 2023-04-18 17:14
Daewoong Pharmaceutical's Envlo to enter the global market in full swing with filing for product license in three ASEAN countries 2023-03-22 21:20
Maypharm CO, LTD., launched a new CE filler: Multi-layered Phasic Hyaluronic Acid with lidocaine and CE approved MayFill Filler 2023-02-20 19:03
Daewoong Pharmaceutical Reaches Sales of KRW 1.16 Trillion in 2022, Fexuclue Leads The Highest Revenue 2023-02-20 12:29
Daewoong Pharmaceutical begins the first administration of the Bersiporocin, new treatment for idiopathic pulmonary fibrosis, as Phase II clinical trial 2023-02-06 13:00
Daewoong enters exclusive licensing agreement with CS Pharmaceuticals for Bersiporocin in Idiopathic Pulmonary Fibrosis in the Greater China Region 2023-01-31 14:43
Daewoong Pharmaceutical submitted NDA for its global new drug Fexuclue in 11 countries, only 1 year after approval in Korea 2023-01-26 09:14
Daewoong Pharmaceutical announces success in developing a new antidiabetic medication and its aims to enter the market in over 50 countries by 2030 2022-12-06 20:00
Daewoong Pharmaceutical Surpasses KRW 300 Billion in Q3 Revenue as Nabota Sales Grew by 93%, Leading Overall Growth in Revenue 2022-11-15 20:00
1 2 3